Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Conditions: Follicular Lymphoma; Marginal Zone Lymphoma; B-Cell Lymphoma

Interventions: Drug: Zanubrutinib; Drug: Rituximab

Sponsors: H. Lee Moffitt Cancer Center and Research Institute; BeiGene, Ltd.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 7, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments